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ABBREVIATIONS 
 
Abbreviation  Meaning  
aCL Anticardiolipin  
ACR American College of Rheumatology  
AIDS Acquired Immuno-deficiency Syndrome  
ALT Aspartate Lactate Transaminase  
APA Antiphospholipid antibodies  
APS Antiphospholipid Syndrome  
APTT Activated partial thromboplastin time.  
ASROM American Society for Reproductive Medicine  
β2 GP-I β2 glycoprotein-I 
C/S  Caesarean section 
DVT Deep vein thrombosis  
El C/S  Elective C/S  
Em C/S Emergency C/S 
GA  Gestational age  
HCG Human Chorionic gondotrophin  
HELLP Haemolysis elevated liver enzyme low platelet  
IUFD Intrauterine foetal death  
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IUGR Intrauterine growth restriction  
IVF In vitro fertilization  
IVIG Intravenous immunoglobulin  
LA Lupus anticoagulant  
LMWH  Low molecular weight heparin  
NICU  Neonatal Intensive Care Unit  
PE  Pulmonary embolism  
PET Pre-eclampsia  
PIH  Pregnancy induced hypertension  
PROM  Premature rupture of membrane  
RVVT  Ryssell viper venom test  
TTP  Thrombocytopenic purpura 
SLE  Systemic lupus erythematosus  
STS  False positive serological test for syphilis  
SVD  Spontaneous vaginal delivery  
U/S Ultrasound  
VDRL  Venereal disease research laboratory test 
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ABSTRACT 
Antiphospholipid syndrome is an autoimmune disease 
characterized by presence of antibodies such as aCL, AL and  
β2GPI associated with pregnancy losses, thromboembolism, 
intrauterine growth restriction and many adverse maternal 
outcome.  
The objective is to study foetal and maternal outcome in 
treated pregnancies with APS.  
Prospective comparative hospital based study carried out in 
four main maternity units in a period of 1st 2004 of August to 15th of 
March 2005. Informations were collected from patients in the 
referral clinic, the labour room or early after delivery.   
Using simple questionnaire 50 cases of treated pregnancies 
with APS, compared with 100 patients with bad obstetric history as 
control.  
From the study cases, 2 (4%) received low dose aspirin alone 
and 48 (96%) received low dose aspirin plus subcutaneous heparin 
5000 IU twice daily, under gone comparative hospital based study 
with patient with bad obstetric history not known to have 
antiphospholipid antibodies in 4 major hospitals in Khartoum State.  
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Correlation study of gestational age at delivery (P = 0.007),  
poor foetal outcome (P = 0.001), more IUGR in the current 
pregnancy (P = 0.00) and increase incidence of low birth weight 
(P= 0.00) in the study cases compared to the control were found to 
be significant. While there was no significant difference regarding  
PIH, PET, DVT, PE.  
Live birth rate was 68%. Despite improvement of foetal 
outcome there was high incidence of preeclampsia (14%), venous 
thromboembolism (4%), prematurity (30%), IUGR (28%) and foetal 
distress (18%).  
A good predictor of foetal and maternal outcome was 
observed which was their past obstetric history.  
The study concluded that despite treatment antiphospholipid 
syndrome in pregnancy was associated with adverse foetal and 
maternal complications.  
Low dose aspirin and heparin were recommended for 
treatment.  
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  ﻤﻠﺨﺹ ﺍﻷﻁﺭﻭﺤﺔ
ﺘﻌﺘﺒﺭ ﻤﺘﻼﺯﻤﺔ ﻤﻀﺎﺩ ﺍﻟﺩﻫﻴﻨﺎﺕ ﺍﻟﻔﺴﻔﻭﺭﻴﺔ ﻤﺭﺽ ﻤﻀﺎﺩﺍﺕ ﺠﺴﺩﻴﺔ ﺨﺼﻭﺼﻴﺔ ﺘﻤﺘﺎﺯ 
ﺍﻟﺘـﻰ (  1ﺏ)ﺒﻭﺠﻭﺩ ﻤﻀﺎﺩ ﺍﻟﻘﻠﺒﻴﺔ ﺍﻟﺩﻫﻨﻴﺔ، ﻤﻀﺎﺩ ﻤﺎﻨﻊ ﺍﻟﺘﺠﻠﻁ ﻭﻤﻀﺎﺩ ﺍﻟﺴﻜﺭﻴﺎﺕ ﺍﻟﺒﺭﻭﺘﻴﻨﻴـﺔ 
ﺘﺴﺒﺏ ﻋﺩﺓ ﻤﻀﺎﻋﻔﺎﺕ ﻤﻨﻬﺎ ﺇﺠﻬﺎﺽ ﺍﻷﺠﻨﺔ ، ﺍﻟﺘﺠﻠﻁ ، ﻗﺼﻭﺭ ﻨﻤﻭ ﺍﻟﺠﻨﻴﻥ ﺩﺍﺨل ﺍﻟﺭﺤﻡ، ﻭﻤﻭﺕ 
  . ﺎﻓﺔ ﺇﻟﻰ ﺤﺩﻭﺙ ﻤﻀﺎﻋﻔﺎﺕ ﻟﻸﻡﺒﺎﻹﻀ. ﺍﻷﺠﻨﺔ
ﻴﻬﺩﻑ ﺍﻟﺒﺤﺙ ﻟﺩﺭﺍﺴﺔ ﻤﺤﺼﻠﺘﻲ ﺍﻟﻁﻔل ﻭﺍﻷﻡ ﻤﻊ ﺍﻟﻌﻼﺝ ﻋﻨﺩ ﺍﻟﺴﻴﺩﺍﺕ ﺍﻟﺤﻭﺍﻤل ﺍﻟﻼﺘﻲ  
  . ﺘﻡ ﺘﺸﺨﻴﺹ ﺤﺎﻻﺕ ﻤﺘﻼﺯﻤﺔ ﺍﻟﺩﻫﻨﻴﺎﺕ ﺍﻟﻔﺴﻔﻭﺭﻴﺔ ﻟﺩﻴﻬﻥ
 ﻭﺤﺘـﻰ ﻤـﺎﺭﺱ 4002ﺃﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ ﻤﻘﺎﺭﻨﺔ ﻤﺴﺘﻘﺒﻠﻴﺔ ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﺃﻏﺴﻁﺱ 
ﻤﺴﺘﺸﻔﻰ ﺍﻟﻭﻻﺩﺓ ﺃﻤﺩﺭﻤﺎﻥ، ﻭﻤﺴﺘـﺸﻔﻰ )ﻟﻌﺎﺼﻤﺔ   ﻭﺫﻟﻙ ﻓﻰ ﺃﺭﺒﻌﺔ ﻤﻥ ﺍﻜﺒﺭ ﻤﺴﺘﺸﻔﻴﺎﺕ ﺍ 5002
  (. ﺍﻟﺨﺭﻁﻭﻡ، ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻰ ﻭﺃﻡ ﺩﺭﻤﺎﻥ ﺍﻟﻌﺴﻜﺭﻱ
ﺘﻡ ﺠﻤﻊ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﻤﻥ ﺍﻟﺤﻭﺍﻤل ﺍﻟﻼﺌﻰ ﺤﻀﺭﻥ ﺍﻟﻰ ﺍﻟﻌﻴـﺎﺩﺍﺕ ﺍﻟﻤﺤﻭﻟـﺔ ﺃﻭ ﺒﻐﺭﻓـﺔ 
  . ﺍﻟﻭﻻﺩﺓ ﺍﻭ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻤﺒﺎﺸﺭﺓ ﺒﻭﺍﺴﻁﺔ ﺍﺴﺘﺒﻴﺎﻥ ﺃﻋﺩ ﺨﺼﻴﺼﺎﹰ ﻟﻬﺫﺍ ﺍﻟﻐﺭﺽ
ﻬﺎ ﺤﺎﻻﺕ ﺇﺠﻬﺎﺽ ﺃﺠﻨﺔ ﺃﻭ ﻤﻭﺕ ﺠﻨﻴﻥ ﺒﺎﻟﺒﻁﻥ ﺘﻤﺕ ﻤﻘﺎﺭﻨﺔ ﺍﻟﺤﺎﻻﺕ ﺒﺤﺎﻻﺕ ﺤﻤل ﻟﺩﻴ 
  . ﺃﻭ ﻤﻭﺘﻪ ﺒﻌﺩ ﺍﻟﻭﻻﺩﺓ ﻤﺒﺎﺸﺭﺓ ﺩﻭﻥ ﻭﺠﻭﺩ ﻤﻀﺎﺩﺍﺕ ﺍﻟﺩﻫﻴﻨﺎﺕ ﺍﻟﻔﺴﻔﻭﺭﻴﺔ
ﺨﻠﺼﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺃﻥ ﻫﻨﺎﻟﻙ ﻋﻼﻗﺔ ﺇﺤﺼﺎﺌﻴﺔ ﺒـﻴﻥ ﻤﺘﻼﺯﻤـﺔ ﻤـﻀﺎﺩ ﺍﻟـﺩﻫﻨﻴﺎﺕ 
ﺍﻟﻔﺴﻔﻭﺭﻴﺔ  ﻭ ﻤﺩﺓ ﺍﻟﺤﻤل ﻋﻥ ﺍﻟﻭﻻﺩﺓ، ﺤﺎﻟﺔ ﺍﻟﺠﻨﻴﻥ ﻋﻨﺩ ﺍﻟﻭﻻﺩﺓ، ﻭﺯﻥ ﺍﻟﺠﻨـﻴﻥ ﻋﻨـﺩ ﺍﻟـﻭﻻﺩﺓ، 
ﺭ ﻨﻤﻭ ﺍﻟﺠﻨﻴﻥ ﺒﺎﻟﺭﺤﻡ ﻭﻻ ﺘﻭﺠﺩ ﻋﻼﻗﺔ ﺇﺤﺼﺎﺌﻴﺔ ﺒﻴﻥ ﻀـﻐﻁ ﺍﻟﺠﻨـﻴﻥ ﻭﺤـﺎﻻﺕ ﺍﻟـﺘﺠﻠﻁ  ﻗﺼﻭ
ﺒـﺎﻟﺭﻏﻡ %( 86)ﻜﺎﻨﺕ ﻨﺴﺒﺔ  ﺍﻟﻭﻻﺩﺓ ﺍﻟﺤﻴﺔ . ﺍﻟﻤﺨﺘﻠﻔﺔ ﺒﻴﻥ ﻤﺠﻤﻭﻋﺔ ﺍﻟﺒﺤﺙ ﻭﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﻘﺎﺭﻨﺔ 
%( 41)ﻤﻥ ﻭﺠﻭﺩ ﺘﺤﺴﻥ ﻤﻠﺤﻭﻅ ﻓﻰ ﺍﻟﻭﻻﺩﺍﺕ ﺍﻟﺤﻴﺔ ﺇﻻ ﺃﻥ ﻫﻨﺎﻟﻙ ﻨﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻤﻥ ﻀﻐﻁ ﺍﻟﺠﻨﻴﻥ 
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، ﺤـﺎﻻﺕ %(82)، ﻗﺼﻭﺭ ﻨﻤـﻭ ﺍﻟﺠﻨـﻴﻥ ﺒـﺎﻟﺭﺤﻡ %(4)ﺍﻑ ﺍﻟﺴﻔﻠﻰ ﺤﺎﻻﺕ ﺍﻟﺠﻠﻁﺎﺕ ﺒﺎﻷﻁﺭ 
  %(. 81)ﺍﺨﺘﻨﺎﻕ ﺍﻟﻁﻔل ﺃﺜﻨﺎﺀ ﺍﻟﻭﻻﺩﺓ %( 03)ﺍﻟﻭﻻﺩﺍﺕ ﺍﻟﻤﺒﻜﺭﺓ 
ﺨﻠﺹ ﺍﻟﺒﺤﺙ ﺇﻟﻰ ﺃﻨﻪ ﺒﺎﻟﺭﻏﻡ ﻤﻥ ﺍﻟﻌﻼﺝ ﺇﻻ ﺃﻥ ﺍﻟﺤﻭﺍﻤل ﺍﻟﻼﺘﻲ ﻴﻌﺎﻨﻴﻥ ﻤـﻥ ﻭﺠـﻭﺩ 
 ﻴﻭﺼـﻰ ﻤﻀﺎﺩ ﺍﻟﺩﻫﻨﻴﺎﺕ ﺍﻟﻔﺴﻔﻭﺭﻴﺔ ﻴﺘﻌﺭﻀﻥ ﺇﻟﻰ ﻤﻀﺎﻋﻔﺎﺕ ﻋﺎﻟﻴﺔ  ﻟﻜل ﻤﻥ ﺍﻟﻁﻔل ﻭﺍﻷﻡ، ﻭﻟﺫﺍ 
  .   ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻷﺴﺒﺭﻴﻥ ﻭﺍﻟﻬﻴﺒﺎﺭﻴﻥ
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INTRODUCTION 
Definition:  
Antiphospholipid syndrome is an autoimmune disease, first 
described in 1983(1) characterised by antiphosphlipid antibodies and at 
least clinical manifestation, the most common being venous or arterial 
thrombosis and recurrent foetal loss.(2)  
The syndrome occurs in isolation (primary antiphospholipid 
syndrome or in association with connective tissue diseases 
(secondary antiphospholipid syndrome) particularly systemic lupus 
erythematosus.(3) Phospholipids are the basic constituents of cell 
membranes. In contrast to antibodies that target phospholipid-binding 
proteins, there are also antiphospholipid antibodies that bind directly 
to negatively charged phospholipids themselves. These occur in 
patients with infection such as syphilis, infectious mononucleosis(4)and 
AIDS,(5)and following exposure to certain medications.(6)These 
antibodies usually have no clinical sequelae. However, routine assays 
do not readily distinguish between these major antibody subsets. 
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Historical background:   
In 1935, Wassermann identified sera from patients with 
syphilis that reacted with extracts of syphilitic tissues.(7)The 
Wassermann reagin test was originally attributed to antibody reactivity 
against antigens derived from treponema pallidum, until the use of 
normal human and animal tissues was found to give similar results.(8) 
It was not until 1941 that Pangborn isolated cardiolipin 
(diphosphatidylglycerol) from bovine heart, identifying it as the 
antigenic component of the reagin test.(9) Subsequently, the 
combination of cardiolipin lecithin and cholesterol formed the basis of 
the flocculation test for syphilis referred as the venereal disease 
research laboratory (VDRL) test.(8) With the development of more 
specific tests for syphilis, such as the T. pallidum immobilization test, it 
became clear that infections other than syphilis could produce a 
positive Wassermann reagin or VDRL test. 
 In 1952, Moore and Mohr identified 2 circumstances in which 
a biologic false-positive serologic test result for syphilis could 
occur.(10)Transient reactions followed acute viral infections and 
vaccination, whereas persistent (>6 months) reactions were 
associated with autoimmune disorders such as systemic lupus 
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erythematosus, Sjogren's syndrome and rheumatoid arthritis. In 1952, 
Conley and Hartman reported the cases of two patients with 
hemorrhagic disorders who had prolongation of prothrombin time in 
addition to a biologic false-positive serologic test result for 
syphilis.(11)This was the initial description of the "lupus anticoagulant", 
detected by the prolongation of a phospholipid-dependent in-vitro 
coagulation test. Subsequent work confirmed that the lupus 
anticoagulant was attributable to the biologic false-positive serologic 
test result for syphilis (12) and, paradoxically, was associated with in-
vivo thrombosis (13) rather than a bleeding diathesis.    
In 1983, Harris and colleagues described a radioimmunoassay 
for anticardiolipin antibodies that was considerably more sensitive 
than previous binding assays of functional coagulation assays.(14) This 
development and the subsequent conversion to an enzyme-linked 
immunosorbent assay (ELISA)(15) greatly facilitated subsequent 
clinical epidemiologic studies and the description of the 
antiphospholipid syndrome. 
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LITERATURE REVIEW 
Aetiology: 
Phospholipids are the basic constituents of cell membranes. 
Exteriorization of anionic phospholipids to the cell membrane's outer 
leaflet follows cell injury due to many different insults, including 
ischemia, trauma, toxins, and initiation of programmed cell death 
(apoptosis), inflammation, infections, and drug interactions. These 
events may enhance the development of antiphospholipid antibodies 
in some patients. 
Classification:  
Four types of antiphospholipid antibodies (APA) have been 
described : 
• Antibodies that give a false positive serologic test for syphilis (STS). 
• Lupus anticoagulants. 
• Anticardiolipin antibodies. 
• Anti β2-glycoprotein I antibodies.  
False positive serologic test for syphilis (STS):   
When patient sera contain anticardiolipin antibodies, the false 
positive STS occur because the syphilis antigen used in the test is 
embedded in cardiolipin. Thus, a reaction against this cardiolipin will 
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be incorrectly interpreted as being directed against the treponemal 
antigen. 
Lupus anticoagulants:  
 Lupus anticoagulants (LA) are antibodies directed against 
plasma proteins (such as prothrombin or annexin V) that are bound to 
phospholipids.(16-18)Despite the name, the principal clinical 
consequence of LA is thrombosis, not haemorrhage.(19) 
Anticardiolipin antibodies:   
Anticardiolipin antibodies (aCL) react with proteins bound to 
anionic phospholipids, such as cardiolipin and phosphatidylserine 
(e.g. Anti β2-glycoprotein I and annexin V). Different immunoglobulin 
isotypes and subclasses are associated with aCL, including IgG, IgA, 
IgM, and IgG subclasses 1 to 4. Elevated levels of IgG aCL 
(particularly IgG2) incur a greater risk of thrombosis than do other 
immunoglobulin isotypes (20) 
Anti β2-glycoprotein I antibodies antibodies:   
Antibodies to anti β2-glycoprotein I antibodies I (β2-GPI) a 
phospholipid-binding inhibitor of coagulation, are found in a large 
percentage of patients with primary or secondary antiphospholipid 
syndrome (APS). (21) Anti- antibodies directly bind to β2-GPI as 
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opposed to aCL, which frequently bind to a complex of anionic 
phospholipids and β2-GPI. 
Epidemiology:  
Although antiphospholipid antibodies are associated with both 
a propensity for thrombosis and various autoimmune disorders, they 
can also be found in normal asymptomatic individuals.(22-23) In one 
study, 40 of 499 normal blood donors had a positive lupus 
anticoagulant test, and 3 had elevated levels of aCL.(24) 
Antiphospholipid antibodies are more common among young women 
than men. 
Prevalence in pregnant women:  
 These antibodies are also found in a significant percentage of 
pregnant women: Fifteen per cent of women with a history of recurrent 
miscarriage (three or more consecutive losses of pregnancy) have 
persistently positive results for phospholipid antibodies.(25)These 
women have a rate of foetal loss of 90% when no specific treatment is 
given during pregnancy.(26-27) 
 The reported prevalence of aCL in women with 
uncomplicated pregnancies ranges from 0 to 11 percent, with a 
median value of about two percent. (28-36) 
 7
  In a literature review of approximately 14,000 women, the 
prevalence of antiphospholipid antibodies was 5% of normal obstetric 
patients, 24% of women undergoing in vitro fertilization, and 37% of 
women with SLE. (28) 
Pathophysiology: 
The in-vivo mechanisms responsible for thrombosis and foetal 
loss in patients with antiphospholipid syndrome remain unknown, 
although several potential pathogenic pathways have been identified. 
First, antiphospholipid antibodies may interfere with the function of the 
coagulation cascade leading to a procoagulant state.(37) Examples 
include inhibition of the activated protein C and antithrombin III 
pathways, inhibition of fibrinolysis and upregulation of tissue factor 
activity. As previously mentioned, β2-GPI may function as an in-vivo 
anticoagulant(38) and, thus, antibodies that target the molecule may 
interfere with this role. Other proteins that are important in regulating 
coagulation, such as prothrombin, proteins C and S, and annexin V, 
may also be targeted by antiphospholipid antibodies.(37) Finally,  there 
is evidence that the binding of annexin V to procoagulant  surfaces 
may  be inhibited   by antiphospholipid antibodies.(39, 40)  
Several studies have examined the specific interaction 
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between antibodies to β2-GPI and in-vitro endothelial cell function. 
The direct binding of β2-GPI to the endothelial cell surface is 
facilitated by the constitutive negative charge on the surface of 
endothelial cells, enhanced surface expression of negatively charged 
phosphatidylserine during apoptosis(41) and the fact that annexin II 
acts as a receptor for the binding of β2-GPI to cultured endothelial 
cells.(42) Thus, antiphospholipid antibody binding to the endothelial cell 
surface in a β2-GPI-dependent manner leads to endothelial cell 
activation, which is manifested by upregulation of cell surface 
adhesion molecules and increased secretion of interleukin-6 and 
prostaglandins.(43,44,45,46)Because activated endothelial cells promote 
coagulation,(47)this may be a relevant pathogenic mechanism. There is 
also evidence that antiphospholipid antibodies promote the activation 
and aggregation of platelets.(37)  
Data from experimental animals support a pathogenic role for 
antiphospholipid autoantibodies, particularly those with specificity for  
β2-glycoprotein I, in both the generation of thrombosis(48,49) and the 
causation of foetal loss.(49,50) There is also evidence that viral (51) and 
bacterial peptides(52) may induce antiphospholipid antibody production 
in animals and promote thrombosis (51) and foetal loss.(52)  
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Recent work has suggested a direct role for cellular immune 
mechanisms in antiphospholipid syndrome. Peripheral blood 
mononuclear cells proliferate in response to native human β2-GPI, 
and cell culture supernatants from peripheral blood mononuclear cells 
stimulated with β2-GPI showed a predominance of gamma interferon 
production,(53)which has the potential to directly activate endothelial 
cells.  
Finally, it is likely that other factors play a role in determining 
whether patients develop clinical manifestations of antiphospholipid 
syndrome, e.g. a "second hit" may be required for thrombosis and 
foetal loss to occur. Although speculative, this may include traumatic 
injury to the vascular bed, nonimmunologic procoagulant factors or the 
presence of infection leading to cytokine production and endothelial 
cell activation. Recent data have also suggested that the presence of 
antibodies to nuclear lamin B1 nullifies the prothrombotic risk 
associated with lupus anticoagulant in patients with systemic lupus 
erythematosus,(54)although the mechanism by which these 
autoantibodies confer this protective effect remains to be explained.  
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Pathogenesis of obstetrical consequences: 
Thrombus formation, infarction, and vasculopathy are 
assumed to account for many of the clinical manifestations of the 
APS.(55)Experimental models indicate that additional factors may also 
be responsible for adverse pregnancy outcomes,(56) with aCL directly 
causing infertility, foetal loss, and growth restriction. Thus, the 
association of APS and pregnancy complications may not be just an 
epiphenomenon occurring after antecedent endothelial injury.(57, 58) In 
general, these adverse pregnancy outcomes are defined in the 
following way: 
• Infertility refers to a reduced capacity of a couple to conceive and 
produce offspring. 
• Miscarriage is the delivery of a pregnancy, either spontaneously 
(also called miscarriage) or electively, before 20 weeks of gestation. 
A first trimester miscarriage occurs before 13 weeks of gestation, a 
second trimester abortion occurs between 14 to 20 weeks. 
• Recurrent pregnancy loss (also known as recurrent miscarriage) 
refers to two or more consecutive spontaneous miscarriage. 
• Preterm delivery constitutes a live birth or stillbirth after 20 and 
before 37 weeks of gestation. After this period, the birth is 
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considered a term delivery. 
• A foetal demise refers to an intrauterine death at anytime after 10 
weeks of pregnancy. 
Foetal loss is an imprecise term that may be used to refer to an 
abortion or foetal death at a gestational age (e.g. after 10 weeks of 
gestation, in the second or third trimester). Pregnancy loss can mean 
an abortion, foetal death at any gestational week, or delivery of an 
infant of any gestational age that does not survive. The broad usage of 
these terms for case selection in studies of adverse pregnancy 
outcome has contributed to variable, and sometimes conflicting, 
results.      
Effects on trophoblast:  
Normal implantation and foetal development require 
trophoblastic invasion of the uterus and blood vessels, a process that 
may be mediated by plasminogen activator-induced formation of 
plasmin; this subsequently promotes degradation of the decidual 
extracellular matrix. Lupus anticoagulants may impair this process by 
inhibiting plasminogen activator activity.(59,60) Diminished levels of 
annexin V in trophoblasts may also be a significant factor.(61-3)Annexin 
V binds to exteriorized anionic phospholipids to render them non-
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thrombogenic.(64,65)Antiphospholipid antibodies can reduce the levels 
of trophoblast associated annexin V, thereby promoting placental 
villus thrombosis.(62)Support for this hypothesis is that diminished 
levels of trophoblast annexin V have been observed among patients 
with high concentrations of antiphospholipid antibodies and a history 
of recurrent abortion.(61) 
Other possible mechanisms of pregnancy loss:  include: 
• Inhibition of endothelial anticoagulant activity including interference 
with thrombomodulin, protein C and S and/or antithrombin III 
activity.(66,67,68,69)      
•  Crossreaction with platelet phospholipids, thereby producing 
damage that increases platelet adhesiveness and initiates 
thrombosis.(70,71,72,73,74)   
•  Increased production of procoagulant by monocytes.(75)   
•  Inhibition of gonadotropin releasing hormone-induced human 
chorionic gonadotropin (hCG) secretion.(76)  
•  Impairment of fibrinolysis.(77, 78)  
•  Increased endothelial synthesis of von Willebrand factor 
multimers.(79, 80)  
•  Inhibition of β2-GPI anticoagulant functions.(81- 84) 
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Clinical manifestation: 
Antiphospholipid antibodies, such as lupus anticoagulants 
(LA) and anticardiolipin antibodies (aCL) are recognized causes of 
thromboembolic phenomenon, thrombocytopenia, and several 
adverse obstetrical outcomes. This disorder is referred to as the 
primary antiphospholipid antibody syndrome (APS) when these 
antibodies occur alone. It is called secondary antiphospholipid 
syndrome when they are found in association with systemic lupus 
erythematosus (SLE), other rheumatic diseases, and with certain 
infections and drugs. 
Thrombotic manifestations:  
The most common clinical manifestation of antiphospholipid 
syndrome is thrombosis, which can affect the vessels of any organ. 
Venous thrombosis, particularly of the lower limb, occurs in up to 55% 
of patients with the syndrome, half of whom also have pulmonary 
emboli.(85,86,87) Arterial thrombosis involves the brain in up to 50% of 
cases, causing transient ischemic attacks or strokes. Other anatomic 
sites for arterial thrombosis are the heart (25%), causing coronary 
occlusion, and the eye, kidney and peripheral arteries (25%).(85,86,87)  
Finally, vascular occlusion may occur through embolization from a 
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central source such as vegetations on a mitral or aortic valve, which 
are reported in up to 4% of patients with antiphospholipid 
syndrome.(87) Some echocardiographic abnormalities may be detected 
in almost two-thirds of patients with the syndrome, although most of 
these abnormalities are of little clinical significance.(87)  
Obstetrical outcomes:  
Several adverse pregnancy outcomes have been attributed to 
the presence of antiphospholipid antibodies. These include the 
following: 
 Unexplained foetal death after 10 weeks gestation. 
  Early, severe preeclampsia or eclampsia. 
  Foetal growth restriction and abnormal foetal heart rate patterns 
from severe placental insufficiency. 
 Three or more unexplained consecutive spontaneous abortions 
before the 10th week of gestation. This is a very controversial area; 
many investigators believe these antibodies are not a cause of 
embryonic loss before 10 weeks. 
 Pregnancy-related maternal thromboembolic disease (venous 
and/or arterial). 
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In some reports, an increased incidence of in vitro fertilization 
failures have been associated with the presence of antiphospholipid 
antibodies.(28)However, a meta-analysis of seven studies failed to 
confirm this association.(88) 
Difficulties with causality:  
Since antiphospholipid antibodies can be found in normal 
asymptomatic individuals, it is sometimes unclear whether there is a 
causal relationship between these antibodies and a clinical event in 
any one individual, particularly among those with a relatively common 
adverse obstetrical outcome (e.g. spontaneous abortion). Additional 
explanations for the poor predictive value of a given positive LA or 
APA result include the following: 
 Reliance upon non-standardized assays for antiphospholipid 
antibodies and failure to use internationally recognized standards. 
 Failure to control for the severity of co-existing diseases (e.g. 
SLE, diabetes, renal disease, hypertension, and infections) known 
to cause adverse obstetrical outcomes. 
  Failure to recognize co-existing inherited coagulopathies. 
 Inclusion of patients with low positive APA levels among patients 
considered positive. 
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 Broad definitions for case selection in series involving 
pregnancy wastage (preembryonic versus later loss). 
 The variable thrombogenic potential of a given patient's APA. 
 Population heterogeneity in concentrations of clotting, anti-
clotting and fibrinolytic proteins 
Despite these difficulties, significant and reproducible LA 
activity and/or high concentrations of aCL are frequently, but not 
invariably, associated with thromboembolism, recurrent foetal demise, 
intrauterine growth restriction, and severe preeclampsia. It remains 
uncertain as to whether these antibodies promote recurrent early first 
trimester loss. 
Recurrent abortion and foetal loss:  
The presence of antiphospholipid antibodies has been linked 
to recurrent first trimester abortions and foetal demise (usually 
occurring in the early second trimester).(89) Some, but not all, studies 
suggest that patients with antiphospholipid antibodies and SLE and/or 
history of foetal loss, as well as those with specific types of 
antiphospholipid antibodies, may be at an increased risk for such 
adverse obstetrical outcomes. The risk of pregnancy loss in women 
with antiphospholipid antibodies is greatest from the 10th week of 
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gestation onward (foetal period).(90, 91) This is in contrast to pregnancy 
loss in the general population, which is most frequent during the first 9 
weeks of gestation. These facts are acknowledged in the Sapporo 
criteria for obstetric manifestations of the antiphospholipid 
syndrome,(92) in which the patient must have 1 or more otherwise 
unexplained losses in the foetal period up to 34 weeks of gestation, or 
3 or more losses in the first 9 weeks of gestation. There is also 
evidence that women with antiphospholipid antibodies have an 
increased risk of giving birth to a premature infant because of 
pregnancy-associated hypertension and uteroplacental 
insufficiency.(93,26)  
Systemic Lupus Erythematosus (SLE): 
Patients with SLE and antiphospholipid antibodies may be at 
an increased risk for spontaneous abortion, with some correlation 
between the level of IgG aCL and the risk of pregnancy loss,(94) as 
examples:   
 A large review of 10 studies of 554 women with SLE found that 
foetal loss was more common in those with compared to those without 
antiphospholipid antibodies (38% to 59% versus 16%  to 20%), lupus 
anticoagulant (36% versus 13%), or anticardiolipin antibodies (39% 
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versus 18%).(95)  
 In a multicenter study of 368 patients with SLE, spontaneous 
abortion (among other outcomes) was significantly associated with 
elevated levels of IgG anticardiolipin antibodies (P<0.001).(96)  
Risk in unselected populations:  
Whether asymptomatic women with antiphospholipid 
antibodies and no prior adverse pregnancy outcome (no thrombotic 
event or pregnancy complication) have an increased risk of 
complications with pregnancy is also unclear. There are studies 
showing no or little association. 
Among 1449 healthy pregnant women, positive anticardiolipin 
tests occurred infrequently and were rarely associated with adverse 
pregnancy outcome.(30)  
 An elegant study comparing women with spontaneous 
abortion or foetal death with complications were more common among 
women with a history of miscarriage or thrombosis than in 
asymptomatic women (56 versus 17 percent).(97)  
A prospective study of asymptomatic nulliparous women with 
normal pregnancies found to have high-titer IgG aCL before 25 weeks 
of gestation described a higher risk of foetal loss compared to aCL 
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negative controls, 28% versus 7%.(98) 
Foetal growth restriction:  
The link between foetal growth restriction (IUGR) and 
antiphospholipid antibodies is similarly confusing.(99,100)In a 
prospective study of 860 unselected Japanese women evaluated for 
anticardiolipin antibody in the first trimester, the rate of foetal growth 
restriction was higher among the 60 aCL positive compared to 800 
aCL negative women (12% versus 2%. (101) Among patients with 
symptomatic APS, the frequency of IUGR approaches 30%.(26,93) In 
contrast, other studies have not found a higher prevalence of aCL 
among women with growth restricted versus normally grown 
foetuses.(100,102)Excess neurodevelopmental abnormalities have not 
been observed in these children.(103) 
Maternal thromboembolism:  
The risk of thromboembolism among antiphospholipid 
antibody positive patients is highly variable and is exacerbated by co-
existent hereditary coagulopathies (e.g. factor V Leiden).(104) 
In one historic cohort study, 24 percent of thrombotic events in 
women with antiphospholipid antibodies occurred in association with 
pregnancy.(105) 
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 In another prospective study, the risk of thrombosis during 
pregnancy was 5 percent among women with known antiphospholipid 
syndrome.(26) 
Among patient with recurrent pregnancy loss, the risk of 
thrombosis appears to be 15.7 per 100 patient years.(106) 
Preeclampsia:  
Severe, early preeclampsia and HELLP (Haemolysis, Elevated 
Liver function enzymes, and Low Platelet count) syndrome have also 
been associated with antiphospholipid antibodies in some, but not all, 
studies.(98,101,102,107,108)Although it is not useful to screen women with 
mild or near term preeclampsia for APA, testing women with severe 
preeclampsia before 34 weeks of gestation may be justified.(109) 
Catastrophic antiphospholipid syndrome:  
Although most patients with antiphospholipid syndrome 
develop venous or arterial thrombosis at a single anatomical site, a 
minority present with multiorgan involvement of rapid onset that is 
associated with high mortality. In recognition of the dramatic nature of 
the clinical presentation, this has been called "catastrophic,"(110) which 
some have attributed to a "thrombotic storm."(111) Because of the 
relative infrequency of this presentation, estimated to be 0.8% in one 
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large series,(112)clinical experience is based upon case series. Patients 
are arbitrarily required to have at least 3 different organ systems 
involved, with symptoms developing over a period of days to weeks. 
Although large-calibre vessels may be affected, typically there is an 
acute thrombotic microangiopathy affecting small-calibre blood 
vessels in multiple organs: 50% of cases included the kidneys, lungs, 
central nervous system, heart and skin. Although there are similarities 
to thrombotic thrombocytopenic purpura (TTP), there are several 
differences.(113) For example, TTP is more likely if there is a history of 
a viral prodrome, fever, profound rather than moderate 
thrombocytopenia, schistocytes on the peripheral blood smear, less 
severe renal impairment, purpura and histopathologic evidence of 
platelet thrombi. In addition, there is recurrence in 64% of cases with 
TTP but this is very rare in catastrophic antiphospholipid syndrome. 
An important difference in the management of these 2 conditions is 
that anticoagulation is essential for antiphospholipid syndrome but is 
inappropriate for TTP. Both conditions may be complicated by 
disseminated intravascular coagulation in about 25% of the cases. 
The disseminated intravascular coagulation may be clinically silent, 
cause thrombosis or bleeding, and is characterized by several 
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laboratory abnormalities, including prolongation of the prothrombin 
time and the partial thromboplastin time, low levels of fibrinogen, 
antithrombin III and protein C, as well as elevated D-dimer 
concentrations.(100,114) Mortality is usually a consequence of multiorgan 
failure and is as high as 50%(100,114) in patients with catastrophic 
antiphospholipid syndrome.  
Diagnosis: 
Classification criteria and diagnosis:  
Criteria for the classification of patients with definite 
antiphospholipid syndrome,(92)developed in 1998; provide a basis for 
including patients with the syndrome in research protocols rather than 
a guide to diagnosing the syndrome in individual patients. In order to 
fulfil the "Sapporo criteria", patients must have either vascular 
thrombosis or foetal loss and demonstrate evidence of 
antiphospholipid antibodies either by the detection of anticardiolipin 
antibodies or a positive lupus anticoagulant. Autoantibodies must be 
detected on at least 2 occasions 6 weeks apart in order to distinguish 
persistent autoimmune antibody responses from transient responses 
caused by infection or drug exposures. These classification criteria 
have been evaluated(115)and reported to have a sensitivity of 71% and 
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a specificity of 98%, suggesting that the threshold for inclusion is high 
and that most cases have "definite" antiphospholipid syndrome. Thus, 
comparable to the situation encountered with the American College of 
Rheumatology (ACR) classification criteria for systemic lupus 
erythematosus,(116)whereby some patients with a diagnosis of 
systemic lupus erythematosus do not meet the ACR criteria, there are 
likely to be patients with the antiphospholipid syndrome who do not 
meet the Sapporo criteria because of the presence of unusual clinical 
manifestations of the syndrome. For example, clinical manifestations 
associated with the antiphospholipid syndrome that are not part of the 
classification criteria include livedo reticularis, cardiac valve disease 
and transient cerebral ischemia, and laboratory manifestations include 
haemolytic anaemia and thrombocytopenia. Thus, in clinical practice a 
diagnostic work-up for antiphospholipid antibodies should be 
considered in all patients with venous or arterial thrombosis and foetal 
loss for which there is no alternative explanation, particularly in the 
presence of recurrent manifestations. Likewise, unexplained 
thrombocytopenia, haemolytic anaemia and prolongation of any 
phospholipid coagulation tests should lead to determination of 
antiphospholipid antibody status. 
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When to evaluate for antiphospholipid antibodies:  
 Given the confusion surrounding causality and association 
with adverse outcomes, the population that should be evaluated for 
antiphospholipid antibodies is controversial. It is recommend that 
patients with the following pregnancy complications should be tested 
for the presence of LA and aCL antibodies: 
 Unexplained stillbirth or foetal death after 10 weeks of gestation. 
 Severe intrauterine growth retardation prior to term. 
  Severe preeclampsia at <34 weeks of gestation. 
As previously mentioned, it is less clear whether patients with 
recurrent first trimester loss (prior to 10 weeks) should be evaluated. 
In one study, more than 80% of patients with recurrent pregnancy loss 
and antiphospholipid antibodies had at least one stillbirth.(117) 
Moreover, the combination of antiphospholipid antibodies and a prior 
stillbirth was associated with higher sensitivity and specificity for 
recurrent pregnancy loss than was the combination of 
antiphospholipid antibodies and recurrent first trimester loss (84 and 
76 percent versus 50 and 6 percent, respectively).(117)Thus, some 
clinicians advocate that antiphospholipid antibodies screening should 
be limited to those patients with recurrent pregnancy loss and an 
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unexplained foetal death or no more than one live birth.(114)Other 
clinicians, however, advocate that patients with two or more 
unexplained spontaneous abortions before 10 weeks of gestation 
should be screened. 
Reproductive age women with the following clinical features 
and/or disorders should also be evaluated for antiphospholipid 
antibodies: (109) 
 False positive syphilis serologies. 
 Nontraumatic thromboembolism. 
 Stroke.  
 Systemic lupus erythematosus. 
 Haemolytic anaemia. 
  Transient ischemic attacks or amaurosis fugax. 
  Livedo reticularis. 
 Unexplained prolongations of the activated partial 
thromboplastin time (aPTT). 
 Unexplained thrombocytopenia 
Detection of antiphospholipid antibody:   
A detailed discussion of the diagnosis of the antiphospholipid 
antibody syndrome is presented separately. To facilitate an 
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understanding of the treatment of these women, the diagnostic criteria 
are repeated in this section.  
Definite APS is considered present if at least one of the 
following clinical criteria and at least one of the following laboratory 
criteria are satisfied: 
 Clinical-either one or more episodes of venous, arterial, or small 
vessel thrombosis ،and/or morbidity with pregnancy. Also provides 
a detailed discussion concerning the specific complications with 
pregnancies that satisfy these criteria. 
 Laboratory: The presence of either IgG and/or IgM 
anticardiolipin antibody (>20 aCL-IgG (GPL) or aCL-IgM (MPL) 
units measured by a standardized enzyme-linked immunosorbent 
assay for β2-GPI -dependent anticardiolipin antibodies, and/or 
lupus anticoagulant activity; the antibodies and/or activity should be 
found on two or more occasions, at least six weeks apart. 
There is no standardized assay for lupus anticoagulant 
activity. Thus, confirmatory tests are required. This can be performed 
by employing an aPTT assay with platelet poor plasma, documenting 
absence of improvement with the addition of excess normal plasma 
(i.e. mixing studies), and confirming phospholipid specificity by adding 
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an additional source of phospholipid to counteract the antibody.(118,119) 
This can be in the form of hexagonal phase phospholipid, or 
phospholipid from formalin-fixed or freeze-dried platelets. 
Multiple tests should be performed when the clinical index of 
suspicion is high, since a single test will detect only 60 to 80 % of 
cases.(118)Furthermore, the test chosen, the source of the reagents, 
and instruments used in the assay all affect the ability to detect a 
lupus anticoagulant. 
These confirmatory tests are consistent with the recently 
published guidelines concerning the detection of lupus anticoagulant 
activity.(120)Such activity is verified if the following results are obtained: 
 Prolonged phospholipid-dependent coagulation should be 
demonstrated on a screening test, such as activated partial 
thromboplastin time, kaolin clotting time, and others. 
 Mixing with normal platelet-poor plasma should not correct the 
prolonged coagulation time. 
 The prolonged coagulation time is shortened or corrected by the 
addition of excess phospholipid. 
 Other coagulopathies are excluded. 
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False negative screening tests are increased in pregnancy, 
possibly due to the enhanced concentration of circulating clotting 
factors (i.e. factor VIII).(121) Such changes do not affect the dilute 
Russell Viper Venom Test (RVVT)  
Management: 
Studies of different treatment regimens:  
Women with the antiphospholipid antibody syndrome are at 
increased risk for foetal loss, especially during the late first trimester 
and second trimester. Several treatment regimens have been 
evaluated to improve pregnancy outcome in these women. The 
following clinical observations were obtained primarily in women with 
antiphospholipid antibodies and a prior history of two or more foetal 
losses. 
Prednisilone and aspirin: 
Early studies suggested that the combination of 
corticosteroids and low dose aspirin reduced the risk of adverse 
pregnancy outcome.(26,122)However, subsequent reports were unable 
to confirm this benefit.(123) In addition, steroid therapy was associated 
with side effects such as premature rupture of membranes, preterm 
delivery, foetal growth restriction, infection, preeclampsia, diabetes, 
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osteopenia, and avascular necrosis. (123-126) 
Heparin and aspirin:  
A number of studies have demonstrated successful pregnancy 
outcomes in women treated with heparin and low dose 
aspirin:(127,128,129) 
 In one trial, aspirin was given to all patients, beginning prior to 
conception.(126)As soon as a viable intrauterine pregnancy was 
confirmed, patients were then randomized to receive either 
prednisone (20 mg every 12 hours) or heparin (10,000 units 
subcutaneously every 12 hours) for the remainder of the 
pregnancy. The heparin dosage was adjusted until a midinterval 
aPTT was similar to baseline levels. Both treatments resulted in 75 
percent live birth rates. However, the incidence of preterm delivery, 
usually from premature rupture of membranes or preeclampsia, 
was higher with the prednisone-aspirin combination 
 Another report evaluated the efficacy of combination therapy 
with heparin and aspirin versus aspirin alone.(129) Aspirin was 
initiated in all patients once pregnancy was confirmed with a 
positive urine pregnancy test. Ninety patients were subsequently 
randomized to either low dose aspirin alone (75 mg every day) or 
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low dose aspirin and subcutaneous heparin (5000 units 
subcutaneously every 12 hours) once a foetal heart beat was 
established via ultrasonography. Combination therapy resulted in a 
significantly higher number of live births than therapy with aspirin 
alone (71% versus 42%). 
Heparin appears to be effective in this setting because it 
potentiates the anti-thrombin effects of antithrombin III and other 
endogenous antithrombin effectors, increases levels of factor Xa 
inhibitor, inhibits platelet aggregation, and binds to antiphospholipid 
antibodies rendering them inactive.(130) Although low molecular weight 
heparin is currently generally used, its efficacy in this clinical setting, 
compared with unfractionated heparin, has not been evaluated. 
Aspirin: 
A few studies have shown that low dose aspirin alone is 
associated with successful pregnancy outcomes.(131-133) In addition to 
its antiplatelet effects, low dose aspirin enhances leukocyte-derived 
interleukin-3 production, which stimulate normal trophoblast growth 
and hormonal function.(134) 
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Recommendations for treatment:  
It is recommended different treatment regimens in pregnant 
women with antiphospholipid antibodies based upon the presence or 
absence of some combination of the following additional clinical 
features: 
 Group 1: Women with antiphospholipid antibodies and a 
diagnosis of the antiphospholipid antibody syndrome, but without a 
history of a non-placental vascular thrombotic event (e.g. deep 
venous thrombosis). 
  Group 2: Women with antiphospholipid antibodies and a history 
of two or more unexplained spontaneous abortions before 10 
weeks of gestation. Such women do not necessarily fulfil the 
criteria for the diagnosis of the antiphospholipid antibody 
syndrome. There is controversy regarding the utility of 
anticoagulant therapy in these patients. 
 Group 3: Women with antiphospholipid antibodies, a diagnosis 
of the antiphospholipid antibody syndrome ،and a history of a 
thrombotic event (non-placental thrombosis). These women are 
distinguished from group1, women because they should already be 
chronically anticoagulated independent of pregnancy. 
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 Groups 1 and 2:  The management of these women is based 
upon combined therapy with aspirin and heparin: 
 A baby aspirin (81 mg per day) is begun as soon as conception 
is attempted.(135) 
 Subcutaneous heparin (10,000 units every 12 hours) is added 
as soon as a viable intrauterine pregnancy is documented, 
generally at approximately seven weeks of gestation. 
The heparin dose is then adjusted to achieve a midinterval 
aPTT level, which is similar to baseline levels. Heparin should be 
continued until term and stopped once labour has begun. It is 
subsequently resumed postpartum (12 hours post-caesarean section 
and 6 hours post-vaginal birth) and either continued or replaced with 
warfarin (stopping the heparin when the INR is therapeutic) for six 
weeks. This recommendation is different than that for patients with a 
history of maternal thrombosis (see below for recommendations for 
group 3. 
For patients undergoing amniocentesis or scheduled 
induction, heparin should be discontinued the night before the 
procedure and resumed six hours post-amniocentesis or post-vaginal 
birth.(135) Among those with scheduled caesarean delivery, heparin 
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should also be discontinued the night before the procedure and 
resumed 12 hours post-procedure. (135) 
Heparin-induced osteoporosis with fracture has been reported 
as a complication in up to two percent of pregnant women on long 
term heparin therapy.(136)Recovery of bone density occurs postpartum 
after the heparin is discontinued; it is unclear, however, if the recovery 
is complete. Supplemental calcium (e.g. 1500 mg calcium carbonate), 
vitamin D ،and weight bearing activity (e.g. walking) are recommended 
to minimize the severity of bone loss.  
Alternatively, we prefer to use low molecular weight heparin 
(LMWH) with an initial weight adjusted dose: enoxaparin 1 mg/kg sq 
once daily or dalteparin 50 U/kg sq once daily. The dose is then 
titrated to maintain a peak anti-factor Xa level of 0.2 to 0.3 U/mL four 
hours after injection in each trimester.  
LMWH has the advantages of once a day dosing and lower 
risks of haemorrhage, thrombocytopenia, and osteoporosis, although 
it is generally more expensive than unfractionated heparin. Caution 
must be exercised near term because of the risk of epidural 
haematomas associated with LMWH therapy in patients receiving 
regional anaesthesia. Thus, LMWH therapy should be stopped at 36 
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weeks of gestation, or earlier if preterm delivery is anticipated, with the 
substitution of unfractionated heparin therapy.(137,138) 
Warfarin is teratogenic and is usually contraindicated in 
pregnancy in the United States. Group 3, Women with APS and a 
history of thrombosis (even remote) should already be chronically 
anticoagulated, of whom most are being given warfarin. As 
mentioned, warfarin is a well-known teratogen. There is no consensus 
about the optimal management of such patients who are planning 
pregnancy. The potential risks and benefits of any strategy must be 
discussed in depth with the patient and her family. Therapeutic 
recommendations broadly include two options: 
 Replacing warfarin with heparin before conception and 
continuing heparin throughout gestation. This probably carries the 
least risk of direct toxicity to the foetus, but is associated with the 
highest risk for maternal complications (e.g. osteoporosis). 
 Replacing warfarin with heparin as soon as pregnancy is 
established. This must be performed prior to the sixth week of 
gestation to avoid warfarin-induced embryopathy. This may be an 
option with women with regular periods who can be relied upon to 
obtain a blood pregnancy test as soon as a missed period occurs. 
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Some investigators (PHS) believe that warfarin should be 
replaced with heparin before conception whenever possible to avoid 
the potential teratogenic risk of the oral anticoagulant in early 
gestation. Awaiting a positive pregnancy test before discontinuing 
warfarin is a less reliable option, because of inadvertent exposure to 
teratogenic risk after the sixth week of gestation. 
In either case, we recommend low dose aspirin and full 
anticoagulation during pregnancy because of the increased risk of 
maternal venous and arterial thrombotic complications during 
pregnancy.(105)Full anticoagulation is defined as a PTT that is 1.5 to 
2.0 times the control value. Heparin or low molecular weight heparin 
can be administered. Details concerning exact dosing for heparin or 
LMWH are discussed separately. Anticoagulation may be switched to 
warfarin postpartum.  
Pregnant women with antiphospholipid antibodies alone: 
 There is a paucity of data upon which to guide management 
of pregnant women with antiphospholipid antibodies alone who do not 
fulfil the diagnostic criteria for the APS and who have the following 
clinical features: 
 No prior pregnancies. 
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 No more than one unexplained spontaneous abortion before 10 
weeks of gestation. 
  No history of thrombosis. 
During a first pregnancy, for example, such untreated women 
with antiphospholipid antibodies have a greater than 50 percent 
chance of a successful pregnancy.(123,139)Therapeutic options for these 
women include no therapy, low dose aspirin alone, or low dose aspirin 
and prophylactic heparin (10,000 to 15,000 units daily).(137) Treatment 
decisions should be made on an individual basis. One of us (PHS) 
recommends either no therapy or low dose aspirin alone in these 
patients. Another view (CJL) is to treat only those patients with a 
documented lupus anticoagulant or anticardiolipin antibodies of ≥  50 
GPL or MPL units with low dose aspirin and prophylactic doses of 
heparin. 
Presence of antiphospholipid antibodies alone in a 
woman undergoing in vitro fertilization:  
The presence of antiphospholipid antibodies alone does not 
appear to adversely affect pregnancy rates or outcome in patients 
who are undergoing in vitro fertilization (IVF).(140,141) A meta-analysis 
by the American Society for Reproductive Medicine (ASRM) Practice 
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Committee found that assessment of antiphospholipid antibodies was 
not indicated among couples undergoing IVF and treatment was not 
justified in this population based upon existing data.(88)This issue 
remains controversial because of the heterogeneity of these studies 
and the different APA assay methodologies used.(142,143)As an 
example, the American Society for Reproductive Immunology 
Antiphospholipid Antibody Committee strongly disagreed with the 
ASRM recommendation and called for studies to confirm under what 
circumstances evaluation and treatment of women with APAs 
undergoing fertility therapy are important.(142) We currently do not 
recommend treating these women with antithrombotic therapy.                      
Treatment failure: 
  Some women have adverse pregnancy outcomes despite 
treatment with low dose aspirin and heparin. In these cases, 
consideration of other, less well studied, and potentially more morbid 
therapies is an option during the next attempted pregnancy. 
Intravenous Immunoglobulin:  
If heparin and aspirin therapy fails, intravenous gamma 
globulin (IVIG) (0.4 g/kg per day for five days each month during the 
next attempted pregnancy) may be effective.(144,145)One study, for 
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example, evaluated IVIG in five patients with a history of 17 
unsuccessful pregnancies; four were also treated with heparin and 
four received low-dose aspirin (81 mg/day).(145) Three women gave 
birth to healthy term infants, and a fourth delivered an infant 
diagnosed with foetal distress at 32 weeks. 
However, results of a multicenter, randomized pilot study 
found no benefit with the addition of IVIG to a low-dose aspirin-
heparin regimen.(146) Among 16 women with well-documented APS, 
treatment with the immune globulin did not significantly improve the 
rates of preeclampsia, IUGR, foetal distress, and neonatal intensive 
care unit admission, or the gestational age at delivery and birth 
weight. There was a trend toward fewer cases of IUGR. It is unclear 
whether this lack of benefit extends to those who fail initial treatment 
with low-dose aspirin plus heparin. 
Prednisone and Aspirin:   
If IVIG fails, prednisone (20 to 40 mg/day) and low-dose 
aspirin can be tried in the next pregnancy. (126,129,147) Prednisone is 
associated with an increased risk of gestational diabetes, premature 
rupture of membranes, and hypertension.(148) In addition, prednisone 
can potentiate the osteopenia effects of heparin. The drug results in 
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an 8 percent reduction in bone density with doses as low as 10 
mg/day for 20 weeks in nonpregnant patients.(148)For this reason, the 
combination of prednisone and heparin is generally not 
recommended. Calcium supplementation is mandatory in this setting. 
The increased risk of premature rupture of membranes 
(PROM) with prednisone therapy likely reflects the inhibitory effects of 
glucocorticoids on foetal membrane extracellular matrix 
synthesis.(149)Alternatively, PROM may be the result of prednisone's 
stimulatory effects on foetal membrane, placental, and decidual 
corticotropin releasing hormone.(150) 
Plasmapheresis: 
 There are two reports in which plasmapheresis was used to 
remove antiphospholipid antibodies in an attempt to avoid 
spontaneous abortion in women with multiple previous 
miscarriages.(151,152)One report performed repeated exchanges of 
approximately three to four treatments per week starting at the 14th 
week of pregnancy and continuing until successful delivery; the other 
performed a total of six exchanges beginning at the 24th week 
followed by successful caesarean delivery at week 29. Both 
documented a reduction in antibody titres following plasmapheresis. 
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Others: 
 Experimental studies in animals have also shown a dramatic 
reduction in foetal loss by the administration of interleukin-3, which 
may act by increasing plasminogen activator activity and by directly 
stimulating trophoblast growth and hormone production.(134,153)The 
applicability of this observation to humans is uncertain. 
Pregnancy monitoring: 
 Women with APS should be counselled regarding the medical 
and obstetrical consequences of the disorder prior to pregnancy. 
During pregnancy, close maternal and foetal monitoring are indicated 
to allow timely intervention in the event of maternal or pregnancy 
complications. In addition to routine prenatal care, surveillance should 
include: (137) 
Initial maternal echocardiography to exclude the presence of 
valvular vegetations; 24 hour urine collection for creatinine clearance 
and protein; and assessment of serum AST/ALT at the beginning of 
the pregnancy to assess for and/or exclude underlying cardiac, renal, 
or liver disease, respectively.  
Weekly assessment of the patient's platelet count during the 
first three weeks of heparin therapy and monthly thereafter, given the 
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potential for heparin-induced thrombocytopenia. Education regarding 
the signs and symptoms of thromboembolic disease. 
Frequent assessment of maternal weight, blood pressure, and 
urine protein to rule out preeclampsia. Renal and liver function tests 
and platelet count should be monitored in patients with signs or 
symptoms suggesting preeclampsia or HELLP syndrome. 
Early sonography to establish a definitive due date followed by 
serial sonograms (every four to six weeks starting at 18 to 20 weeks 
of gestation) to evaluate foetal growth. 
Consider umbilical artery Doppler flow analyses in the setting 
of IUGR as an adjunct to foetal assessment. Use of this technique in 
the foetus suspected to have IUGR is associated with a reduction in 
perinatal mortality and morbidity.(154) 
Foetal heart rate and biophysical profile testing beginning at 
32 to 34 weeks of gestation or earlier if foetal or maternal 
complications are diagnosed prior to 34 weeks. 
Early delivery for deteriorating maternal or foetal condition. 
More intensive maternal and foetal monitoring should be performed 
when preeclampsia or IUGR is detected, and in women with poor 
obstetrical histories or active medical problems. 
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Prognosis: 
The prognosis for pregnancy outcome in those with 
antiphospholipid antibodies depends upon the patient's prior medical 
and obstetrical history and whether they have been treated. 
In women with a prior history of two or more foetal losses, 
there is a 70 to 80 percent live birth rate for patients treated with some 
combination of the above modalities.(126,155-159) However, even among 
patients with live births, there is an increased risk of complications 
relating to the pregnancy, including preeclampsia, prematurity, foetal 
distress and intrauterine growth retardation.(93) 
Nevertheless, babies who are born, although at increased risk 
of prematurity, appear to be essentially healthy and grow normally. As 
an example, in one study of 55 infants born to women with 
antiphospholipid antibodies (many of whom were premature), no signs 
of malformations, thromboses, neurodevelopmental delay, or 
significant problems were observed after five years of life.(160) 
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OBJECTIVES 
 
To study the foetal and maternal outcome in treated 
pregnancies with antiphospholipid syndrome. 
• To compare the treatment used in patients with antiphospholipid 
syndrome (APS) and in patients with bad obstetric history.  
• To review the pregnancy complications in APS. 
• To study and compare the mode of delivery and miscarriage rate. 
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PATIENTS AND METHODS  
2.1. Study Design:  
Observational, prospective, hospital-based study. 
2.2. Study Area:  
This study was conducted at 4 major hospitals in Khartoum 
State, which are highly referral centre from all over Sudan. Namely: 
1- Soba University Hospital (SUH), which is the tertiary hospital, 
located in South-east Khartoum, where there is the foetal unit and it 
is a main referral unit for fetal medicine, and where doctors, 
students, and other medical staff get training.  
2-  Omdurman Military Hospital (MH): the main referral for military 
personnel.  
3- Omdurman Maternity Hospital (OMH): The only exclusive maternity 
hospital in Sudan. 
4-  Khartoum Teaching Hospital (KTH): the main referral hospital from 
all over the Sudan. 
2.3. Study period:  
The data was collected from August 2004 to March 2005. 
2.4 Study population:  
a- Cases already diagnosed pregnant women with primary 
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antiphospholipid syndrome(APS), on clinical background aided by 
laboratory investigations for antiphospholipid antibodies, namely 
Anti-Cardiolipin antibodies(ACL) and Anti-lupus antibodies(LA). 
b-  Control: those women with bad obstetric history, which means 
women with repeated fetal losses in the form of Intrauterine 
Foetal Death (IUFD), preterm labour or early neonatal deaths. 
Not known to have Antiphospholipid anti-bodies.   
2.5 Inclusion criteria:  
Pregnant women with APS and pregnant women with bad 
obstetrics history not known to have APS. 
2.6 Exclusion criteria: 
 1.  All pregnant women who did not fulfill the criteria above. 
 2. Those who refused to participate in the study.   
2.7 Consent: Verbal consent from the treating doctors and the 
patients were obtained. 
2.8 Sample size: 
 According to the equation below = 50. 
N =  z2 x p q 
             d2 
N= Sample size 50.      Z Statistical = 1.96 P. Prevalence = 3% 
Q Probability of failure at  95%.  Desired margin of error = 0.5. 
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2.9. Study Technique: 
     Data was collected by direct interview using simple 
questionnaire during the antenatal visits, the delivery suits, or after the 
delivery in the early purepeurium. Patients undergone serological 
investigation before embarking on their pregnancies or during the 
early antenatal period because of their previous obstetric history.  
   As soon as the patient was considered to be pregnant with 
APS, she was put on low dose aspirin (100mg) alone as early as the 
pregnancy detected, or in combination with heparin (5000 I.U) 
subcutaneous twice per day as cardiac pulsation detected, or at seven 
to eight weeks from the last missed period. Only two patients received 
aspirin decided by the treating doctors, while the rest of study cases 
received combination of low dose aspirin plus heparin. 
2.9.1. Research team:  
This included the author who completed the questionnaire  
and followed the patients. 
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2.9.2 Research tools:  
Details of adopted questionnaire concerning the following data 
were obtained: 
i. Personal data. 
ii. Obstetric history.  
iii. Time, methods and results of diagnosis. 
iv. Antenatal complications. 
v. Gestational age at delivery. 
vi. Mode of delivery.  
vii. Foetal outcome. 
viii. Resuscitation and Apgar score. 
ix. Need for admission to NICU. 
x- Type of treatment. 
2.9.3.  Measurements: 
2.9.3.1. Partial Thromboplastin Time (PTT): 
Done in the initial assessment of patients on heparin aiming at 
Test of (1.5 to 2.5 of the controlling second) 
 2.9.3.2. Platelet count:  
serial count in monthly duration for follow up the patients. 
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2.9.3.3. Fetal assessment:  
After delivery the fetal condition assessed regarding need for 
resuscitation, Apgar score at 5 minutes, foetal weight and need for 
admission to NICU. 
Measurement of Intrauterine Growth Restriction (IUGR):  
Antenatally by estimating the foetal weight by ultrasound (U/S) 
using the growth centile chart. IUGR was diagnosed if the fetal weight 
below the 10th centile. After delivery the actual weight versus 
gestational age was plotted on centile chart for diagnosis of IUGR. 
 Mode of delivery was planned during the antenatal period and 
if there was no severe fetal compromise or severe maternal 
complications, the pregnancy allowed to go to term or 37 to 38 weeks 
for those who were planned for elective caesarian section. 
2.10. Data analysis:  
The data was analyzed using computer program the Statistical 
Package for Social Sciences System (SPSS-11). 
Chi-square test was used and a P-value of less than 0.05 was 
considered statistically significant, and the data presented in form of 
tables and figures. 
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RESULTS 
A total of 50 cases of pregnant women with antiphospholipid  
syndrome 2 (4%) on low dose aspirin and 48 (96%)  on low dose 
aspirin  plus heparin diagnosed on laboratory basis, all of them with 
Anticardiolipin antibody positive, and 100 women with bad obstetric 
history were studied concerning their past obstetrical history, 
antenatal complication and the outcome of pregnancy, as control. 
The demographic variables, which were not, matched in the 
study shown below (age group, residence, level of education, duration 
of marriage and duration of disease since diagnosis).   
Regarding age distribution among cases and control. It was 
found that in the cases, 1(2.0%) below 20 years old, 27 (54%) were in 
the age group between 20-29 years, and 22 (44.%) were in the age 
group between 30 - 39 years, while in the control group, 2 (2%) were 
below 20 years, 42 (42%)  were in the age group between 20-29 
years old, 45 (45%) were in the age group between 30-39 years old 
and 11 (11%) were in the age group between 40 - 49 years old 
respectively (Fig.1).  
Concerning the residence of cases compared to control, It was 
found that, 30 (60%) were from Omdurman, 17 (34%) were from 
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Khartoum and 3 (6%) were from Khartoum North in the cases. While 
64 (64%) were From Omdurman, 31(31%) were from Khartoum and 5 
(5%) were from Khartoum North respectively in the control group  
(Fig. 2).  
Regarding level of education, in the cases, 2 (4%) were 
illiterate, 32 (64%) had primary or secondary schooling, 15 (30%) 
were graduate and 1 (2%) was postgraduate. While in the control 
group, 13 (13%) were illiterate, 74 (74%) had secondary or primary 
schooling and 13(13%) were graduate (Fig. 3).   
Concerning the duration of marriage among cases and 
control, it was found that, 25 (50%) were married for 1-5 years, 22 
(44%) were married for 6- 10 years and 3 (6%) were married for 11-15 
years, compared to the control group, 9 (9%) were married for 1-5 
years, 57 (57%) were married for 6-10 years, 24 (24%) were married 
for 11 - 15 years and 10 (10%) were married for more than 15 years 
(Table 1).  
Concerning the duration of disease since diagnosis among the 
cases, 23 (46%) had the disease form one year, 15 (30%) had the 
disease 2 years, 7 (14%) had the disease 3 years, 4(8%) had the 
disease 4 years and 1 (2%) had the disease 5 years (Table 2).   
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Concerning the parity in the study group, 17 (34%) were para 
0, 1 (2.0%) was primigravida, 31 (62%) were Para one to five and 1 
(2.0%) had > 5 in parity. While in the control group no women with 
para 0, 79 (79%) had one to five and 20 (20%) had more than 5 in 
parity  (Fig. 4). 
Concerning their past history of miscarriage. As an index of 
foetal lost has been found that in the study group, 14 (28%) had no 
miscarriage, 22 (44%) had one to two miscarriage, 9 (18%) had three 
to four miscarriage and 5 (10 %) had more than four miscarriage.           
While in the control group, 67 (67%), 26 (26%), 7 (7.0%) and 0 (0.0 
%) had no past history of miscarriage, 1-2 miscarriage, 3-4 
miscarriage and > 4 miscarriage (p value < 0.05) (Fig. 5). In respect to 
the time of miscarriage, those who had miscarriage in the study group 
13 (26%) and 23 (46%) had first trimester miscarriage (<12 weeks) 
and second trimester miscarriage (≥12 weeks) respectively. 
Compared to the control group 25 % had first trimester miscarriage 
and 8 (8%) had second trimester miscarriage (Fig. 6). 
Concerning other past obstetrical history it was found in the 
study group, 12 (24.0%) had past history of PIH. 16 (32.0%), had past 
history of preeclampsia, 7 (14.0%) had past history abruptio 
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placentae, 3 (6.0%) had deep vein thrombosis(DVT), 1 (2.0%) had 
pulmonary embolism (PE) and 1 (2.0%) had cerebral thrombosis (P > 
0.05). Compared to the control group, 18 (18%) had past history of 
PIH , 32 (32.0%) had preeclampsia, 9 (9.0%) had abruptio placntae 1 
(1.0%)   had past history of (DVT), however non of them had history of 
pulmonary embolism  or cerebral thrombosis (Table 3). 
In term of foetal losses and prematurity 19 (38.0 %) had IUFD 
and 8 (16.0%) had preterm labour. While 35 (35.0%) had IUFD ,and 
38 (38.0%) had preterm labour and 37 (37.0 %) had early neonatal 
deaths (Tables 4 and 5).  
Table 6 shows antenatal complications were as follow, in the 
study group: 10 (20.0 %) had PIH , 7 (14.0 %) had PET , 2 (4 .0%) 
had DVT, 7 (14.0%) had  abruptio placntae , while there was non of 
the studied patients had antenatal  pulmonary embolism  or cerebral 
thrombosis. In contrast to the control group: 17 (17.0 %) had PIH, all 
of them progressed to PET. However non of them had abruptio 
placentae, DVT and PE or cerebral thrombosis. 
Concerning correlation study of intrauterine growth restriction 
in the current pregnancy among cases and control was found to be 14 
(28%) of cases versus 5 (5%) of control group (P= 0.000) this was 
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statistically significant (Table 7). 
With regards to their gestation at delivery, there was increased 
incidence of miscarriage and preterm delivery in the study cases 
compared to the control group: 10 (20.0%) cases <24 weeks were 
miscarriage, 15 (30.0%) were preterm delivery (24-36) weeks and 25 
(50.0 %) were at term (>37). While in the control group: 4 (4.0%) were 
miscarriage, 24 (24.0%) were preterm delivery and 72.0% were at 
term (P = 0.007), this difference was highly statistically significant 
(Table 8). 
Concerning the mode of delivery: vaginal delivery in the study 
group: 21 (42.0%) had vaginal delivery, of them 12 (24.0%) 
spontaneous vaginal delivery (SVD) and 9 (18.0%) had induced 
vaginal delivery. However, in the control group: .46 (46.0%) had 
Vaginal delivery of them 31 (31.0%) had SVD while 19 (19.0%) had 
induced Vaginal delivery. In the study group 29 (58.0%) undergone  
caesarean section (C/S) 21 (42.0%) of them were elective caesarean 
section(ELC/S)  and  8 (16.0%) had Emergency  C/S while 55 (55) 
had C/S in the control group of them 30 (30.0%) had EL C/S of 15 
(15.0%) had Emergency (C/S) (P >0.05) which was not statistically 
significant  (Table 9). 
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Table 10 shows the foetal outcome: in the study group was 
found that, 34 (68.0%) had live births, 6 (12.0%) (IUFD) and 10 
(20.0%) were miscarriage receptively in comparison to the control 
group, 80 (80.0%) alive, 14(14.0%) (IUFD), 4(4.0%) miscarriage and 2 
(2.0%) were early neonatal deaths (P= 0.00), this was statistically 
highly significant. 
Table 11 shows birth weight among cases and control in the  
study group 17 (34.0%) had weight in grams corresponding to their 
gestational age (≥10th centile). However 17 (34.0%) had low birth 
weight to their gestational age (≤ 10th centile), however 17 (34.0%) 
had low birth weight to their gestational age. While in Control group 60 
(60.0%) had appropriate weight for their gestational age, 14 (14.0%) 
had low birth weight and 6 (6.0%) had larger weight for their GA              
(P= 0.000) this was highly statistically significant. 
Concerning resuscitation, 9(18.0%) needed resuscitation, 
while 25 (50.0%) not needed in the study group. However, in the 
control group only 4 (4.0%) needed resuscitation and 74 (74.0%) not 
needed resuscitation (P = 0.028) this was statistically significant 
(Table 12).   
Regarding Apgar score at delivery at 5 minutes, 9(18%) 
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versus 1(1%) had score less than 7 (P<0.05), this difference is  
statistically significant (Table 13). 
Regarding admission to the NICU, 12(24.0%) needed 
admission to the NICU in the study group, while 23 (23.0%) needed 
admission to the NICU in the control group (P= 0.892) this difference 
is not statistically significant (Table 14). 
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Table 1: Duration of marriage among cases and control group 
 in the study 
Duration  (in years) Cases 
n           % 
Control 
n           % 
1 - 5      25     (50%) 09     (9%)  
6 - 10      22    (44%) 57     (57%)  
11 - 15     03    (6.0%)  24     (24%)  
>15     0    (0.0%)  10     (10%)  
Total  50   (100%) 100   (100%) 
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Table 2: Duration of disease among the study cases  
since diagnosis 
Duration of disease (in years) Frequency Percentage 
1 23 46% 
2 15 30% 
3  07 14% 
4 04 08% 
5 01 02% 
Total  50 100.0 
 
 
 
 
 
 
 
 
 64
 
 
 
Table 3: Distribution of past obstetric complications among 
cases and control group in the study 
Past obstetric complications Cases 
n           % 
Control 
n           % 
Pregnancy induced hypertension  12   (24.0%) 18  (18.0%) 
Preeclampsia  16   (20.0%) 32  (32.0%) 
Abruptio placentae  07 (04.0%) 09  (09.0%) 
Deep vein thrombosis  03  (06.0%) 01  (01.0%) 
Pulmonary embolism 01  (02.0%) 00  (00.0.%) 
Cereberal thrombosis  01  (20.0%) 00 (00.0%) 
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Table 4: Correlation study of past obstetric history of previous 
preterm deliveries among study cases and controls 
Previous preterm deliveries Items 
None 1-2 preterm >2 preterm 
Total  
Cases  42 ( 84.0%) 08 (16.0%) 0 (0.00%) 50 (100.0%) 
Controls  62 ( 62.0%) 25 (25.0%) 13 ( 13.0%) 100 (100.0%)
Total  104 (69.3%) 33 (22.0%) 13 (08.7%) 150 (100.0%)
 
X2  = 10.05.                       P. value  = 0.007. 
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Table 5: Distribution of past history of IUFD and early neonatal 
deaths among cases (n=50) and control (n=100) in the study 
 
 Cases 
n           % 
Control 
n          % 
IUFD  19   (38. 0%) 35   (35.0%) 
Early neonatal death  0.0   (0.00%) 37   (37..0%) 
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Table 6: Antenatal complications among study 
 cases and controls 
Antenatal complications Cases 
n           % 
Control 
n          % 
Pregnancy induced hypertension 10  (20%) 17   (7%) 
Preeclampsia  7  (17%) 17  (17%) 
Abruptio  placentae 7  (41%) 00  (00%) 
Deep vein thrombosis 2   (4%) 00  (00.0%) 
Pulmonary embolism  0 (0.0%)  0 (0.0%)  
Cerebral thrombosis  0 (0.0%)  0 (0.0%)  
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Table 7: Correlation study of intrauterine growth restriction 
during the current pregnancy among study cases and controls 
Intrauterine growth restriction Cases 
n           % 
Control 
n          % 
Yes  14  (28%) 05   (05%) 
No  36  (72%) 95  (95%) 
Total  50 (100%) 100 (100%) 
 
X2 = 15.940                                 P  = 0.000 
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Table 8: Correlation study of gestational age at delivery among 
study cases and controls 
Gestational age at  delivery (in weeks) Cases  
< 24 24 - 32 33 - 36 ≥ 37 
Cases  10 (20.0%) 5 (10.0%) 10  (20.0%) 25  (50%) 
Control  04 (08.0%) 8 (8.0%) 16  (16.0%) 72  (72.0%)
 
X2 = 12.099                                 P  = 0.007 
 
 
 
 
 
 
 
 
 70
 
 
 
 
Table 9: Mode of delivery among study cases and controls  
in the study 
Mode of delivery  Cases 
n           % 
Control 
n          % 
Vaginal delivery:  
Spont
aneous  
Induc
ed 
 
12  (24%) 
9 (18%) 
 
31   (31%) 
19  (19%) 
Cesarean section:  
Electiv
e C/S  
Emerg
ency C/S 
 
21  (42%) 
08  (16%) 
 
30 (30%) 
15 (15%) 
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Table 10: Correlation study of foetal outcome among study 
cases and controls 
Outcome   Cases 
n           % 
Control 
n          % 
A live :  
Term  
Pretem  
 
19  (38%) 
15 (30%) 
 
65   (65%) 
15  (15%) 
Foetal losses:    
Miscarriag
e   
IUFD 
 
10  (20%) 
6 (12%) 
 
2 (02%) 
4 (04%) 
Total  50 (100%)  100 (100%) 
 
X2 = 24.33                                    P  = 0.000 
 72
 
 
 
Table 11: Correlation study of birth-weight among study cases 
and controls according to the centile chart  
Birth weight (in centile chart)  Cases 
n           % 
Control 
n          % 
Appropriate for gestational age 
(≥10th - 90th centile) 
17 (34.0%) 60 (60.0%) 
Small for gestational age  
(<10th centile) 
17 (34.0%) 14 (14.%) 
Large for gestational age  
(>90th centile) 
0  (0.0% 06 ( 06.0%) 
 
X2 = 52.140                                   P  = 0.000 
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Table 12: Correlation study of need for resuscitation among 
study cases and controls 
Need for resuscitation    Cases 
n           % 
Control 
n          % 
Yes  09 ( 18.0%) 4 (04.0%) 
No 41 (82.0%) 96 ( 96.0%) 
Total 50  (100.0%) 100 (100.0%)
 
X2 = 44.241                                 P  = 0.000 
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Table 13: Correlation study shows Apgar score < 7 at 5 minutes  
among cases and control 
Apgar score < 7 at 5 minutes   Cases 
n           % 
Control 
n          % 
Yes 09 ( 18.0%) 1 (01.0%) 
No 25 (50.0%)     79 ( 79%) 
 
P < 0.05                      
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Table 14: Correlation study shows admission to the NICU  
among cases and control 
Admission to the NICU  Items 
 Yes No 
Total 
Cases  12 (24.0%) 38 (76.0%) 50(100.0%) 
Control  23 (23.0%) 77 (77.0%) 100 (100.0%) 
Total 35 (23.3%) 115 (76.7%) 150 (100.0%) 
 
X2 = 0.019                                        P  = 0.891 
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 DISCUSSION 
This study was conducted in women who had recurrent foetal 
losses with anti-cardiolipin antibody positive. It was found that good 
predictor of fetal and maternal outcome is their past obstetric history. 
Correlation study found that 7(14%) versus 17 (17%) in the 
study cases compared to the controls had pre-eclampsia in patients 
treated with low dose aspirin and heparin which was not statistically 
significant. Despite that rate of PET as noted in literature which was 
18%,(93) this difference might be related to variation in demographic 
variants among the study groups. Despite of this difference there was 
significant reduction from pretreatment state. 
Maternal thromboembolism was found to be insignificant 
correlation of deep vein thrombosis (DVT) showed 2(4%) versus 
0(0%) However the risk of thrombosis during pregnancy among 
women with APS(26).as it was reported in the literature, there was 
strong association between venous thromboembolism and lupus 
anticoagulant, however there was no association between the 
presence of anticardiolipin antibody and venous thromboembolism.(119)  
The incidence of IUGR was found to be highly significant 
14(28%) VS 5(5%), P=0.000 between cases and controls. As reported 
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in the literature foetal growth restriction approaches 30% (26,93) 
The rate of foetal demise in correlation study was found to be 
6(12%) VS 12(12%), Which was not significant, although it was 
reported that patient with successful treated pregnancies had fewer 
fetal deaths than those with unsuccessful treated pregnancies.(26) 
With regard to gestational age in correlation study there was 
significant difference in study cases compared to control p=0.007 it 
was found that 25.0 (50.0%) versus 72.0 (72.0%) delivered at term 
≥37 weeks. While 15(30.0%) versus 24.0 (24.0%) were preterm this   
highly statistically  significant  as  noted in  literature  43.0% had 
prematurity.(93) This difference may be attributed to measure used in 
the study above (low level of viability was 20 weeks). Correlation 
study shows that 9.0(18.0%) versus 1.0(1.0%) in the cases had Apgar 
score.>7 this is statistically significant, while the incidence of foetal 
distress in two studies approach's 50.0%,(155,93) this difference may 
due to the different measures used (e.g. CTG for intrapartum foetal 
distress). 
Correlation study concerning foetal out come rate of live births 
was found 34.0 (68.0%) 80.0 (80.0%) in cases compared to the to the 
control and foetal losses was found 16.0 (32.0%) versus 20.0 (20.0%) 
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(P= 0.000) this highly statically significant this is inconsistent with 
literature as noted that patient treated with low dose aspirin plus 
heparin result in significantly higher number of live births (70-80%). 
While those who were treated with low dose Aspirin alone result in 
44% of live births.(93.155) 
Despite this small difference which was slightly lower than 
what was noted in these studies and this might be related to the late 
initiation of treatment in the study group compared to those noted in 
the literature. Concerning foetal losses it is consistent with the 
literature. Patient on successful treatment had fewer foetal losses than 
those with unsuccessful treated.(26) 
Concerning resuscitation in correlation study was found to be 
9 (18.0%) versus 4(4%) in the cases compared to the control, needed 
resuscitation (P=0.028), this statistically significant. Despite that, it 
was noted in the literature the incidence of foetal distress was 
50.0%.(93) This difference may be related to the measure used in the 
study. 
Rate of admission to NICU in correlation study was found to 
be 12.0 (24.0%) versus 23.0 (23.0%) in the study cases compared to 
the control  (P = 0.982). 
 79
This difference not statically significant compared to those 
who needed resuscitation this might related to admissions for NICU 
for observation because their mother had several losses or for 
investigation. 
Resuscitation, Apgar score and admission to NICU were taken 
as index of foetal wellbeing in cases compared to the controls, and no 
statistical differences were found between the two groups  
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CONCLUSION 
 
• Treated pregnancies with APS appear to be improved by 
treatment with combination of low dose aspirin plus heparin. 
However, foetal loss still occurs despite treatment.  
• PET, IUGR and prematurity were common even after treatment.  
• Close monitoring and use of antithrombotic therapy was 
effective in reducing foetal wastage despite high incidence of 
obstetric and foetal complications.   
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RECOMMENDATIONS 
 
• Tromboprophylaxis should be considered postpartum for those 
patients with APS.  
• Treated pregnancies with APS have good outcome and less 
maternal and foetal complications.  
• Pregnant women with APS need close monitoring by 
multidicipilinary team and use of antithrombotic agent.  
• Education regarding sign and symptom of thromboembolic 
disease.  
• Early U/S needed to establish definitive due to start treatment.  
• Pregnant women with APS should be followed and delivered in 
tertiary center. 
•  There should be clear protocol of management of patients with 
antiphospholipid syndrome in Sudan.  
• Laboratory diagnosis for the disease should be available in the 
main hospitals.  
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